We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+16.8%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.5B
AUM Growth
+$164M
Cap. Flow
-$95.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
71.22%
Holding
36
New
–
Increased
18
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$49.5M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$16.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$5.91M
4
SAGE
Sage Therapeutics
SAGE
+$2.23M
5
INSM icon
Insmed
INSM
+$1.98M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$165M
2
ALGN icon
Align Technology
ALGN
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$782M
$11.2M 0.45%
396,609
– –
DRNA
27
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.14M 0.25%
500,913
– –
ALIM
28
DELISTED
Alimera Sciences
ALIM
$2.95M 0.12%
200,920
– –
VIRX
29
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.46M 0.1%
33,214
– –
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$1.3M 0.05%
29,500
– –
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$1.03M 0.04%
123,686
– –
ACGN
32
DELISTED
Aceragen Inc
ACGN
$814K 0.03%
4,537
– –
OCGN icon
33
Ocugen
OCGN
$475M
$757K 0.03%
5,049
– –
SPHS
34
DELISTED
Sophiris Bio, Inc.
SPHS
$694K 0.03%
247,000
– –
TRVN
35
DELISTED
Trevena, Inc.
TRVN
$491K 0.02%
546
– –
MLNT
36
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$322K 0.01%
10,138
– –
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2018 Portfolio in Review

As of Q2 2018, Palo Alto Investors held 36 positions worth $2.5B, up 7% from $2.34B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Palo Alto Investors withdrew a net $95.8M in Q2 2018, reducing 2 holdings. Its largest reduction was Abiomed Inc, cutting an estimated $165M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

Against the trend, Palo Alto Investors added an estimated $49.5M to Clovis Oncology, Inc..

  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q2 2018, an estimated $49.5M increase.
  • Palo Alto Investors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $165M.
  • Palo Alto Investors's ten largest holdings make up 71% of its $2.5B portfolio in Q2 2018.
  • Palo Alto Investors opened 0 new positions and closed 0 in Q2 2018.
  • Palo Alto Investors's portfolio value rose 7% quarter-over-quarter to $2.5B.

Based on Palo Alto Investors's 13F filing for Q2 2018, filed 14 Aug 2018.